The Medical Letter on Drugs and Therapeutics
FROM
ISSUE 1733
ISSUE 1733
July 21, 2025
Issue 1733
- Berdazimer Gel (Zelsuvmi) for Molluscum Contagiosum
- Upadacitinib (Rinvoq) for Giant Cell Arteritis
- Teal Wand — An At-Home Cervical Cancer Screening Device
- Onapgo ― An Apomorphine Subcutaneous Infusion for Parkinson's Disease
- In Brief: Low-Dose Chlorthalidone (HemiClor) for Hypertension
- COVID-19 Update: Full Approval for Novavax COVID-19 Vaccine
- COVID-19 Update: mRNA COVID-19 Vaccines and Myocarditis
- COVID-19 Update: mNEXSPIKE — A New Moderna mRNA Vaccine for COVID-19
- Addendum: Drugs for Chronic Heart Failure
- Avmapki Fakzynja Co-Pack for Ovarian Cancer (online only)
- Penpulimab (Anniko) for Nasopharyngeal Carcinoma (online only)
- Prademagene Zamikeracel (Zevaskyn) for Recessive Dystrophic Epidermolysis Bullosa (online only)
- Retifanlimab (Zynyz) for Anal Cancer (online only)
Subscribers: Log in to read full issue. Not a subscriber? Subscribe or purchase issue.
Berdazimer Gel (Zelsuvmi) for Molluscum Contagiosum
July 21, 2025 (Issue: 1733)
Berdazimer 10.3% gel (Zelsuvmi – Ligand), a first-in-class
nitric oxide-releasing agent, has been approved
by the FDA for topical treatment of molluscum
contagiosum in patients ≥1 year old. It is the second
drug to become available in the US...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.